Immunome, Inc. (IMNM), a biotechnology company, announced that it has priced public offering of 10 million shares of common stock at $20.00 per share. The company expects offering to close on February 16, 2024.
Immunome expects offering gross proceeds, before deducting underwriting discounts and commissions and offering expenses, to be $200.0 million.
In addition, Immunome granted underwriters a 30-day option to buy additional 1.5 million common shares at public offering price, less underwriting discounts and commissions.
J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.